TY - JOUR
T1 - A sword of Damocles'
T2 - Patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: A focus group study
AU - Logeman, Charlotte
AU - Cho, Yeoungjee
AU - Sautenet, Benedicte
AU - Rangan, Gopala K.
AU - Gutman, Talia
AU - Craig, Jonathan
AU - Ong, Albert
AU - Chapman, Arlene
AU - Ahn, Curie
AU - Coolican, Helen
AU - Tze-Wah Kao, Juliana
AU - Gansevoort, Ron T.
AU - Perrone, Ronald
AU - Harris, Tess
AU - Torres, Vincent
AU - Fowler, Kevin
AU - Pei, York
AU - Kerr, Peter
AU - Ryan, Jessica
AU - Johnson, David
AU - Viecelli, Andrea
AU - Geneste, Clair
AU - Kim, Hyunsuk
AU - Kim, Yaerim
AU - Howell, Martin
AU - Ju, Angela
AU - Manera, Karine E.
AU - Teixeira-Pinto, Armando
AU - Parasivam, Gayathri
AU - Tong, Allison
N1 - Funding Information:
Competing interests GKR declares he is site investigator of clinical trials sponsored by Sanofi, Otsuka and Reata, principal investigator of the PREVENT-ADPKD clinical trial (funded in part by the NHMRC, Danone Nutricia—manufacturer of bottled water—PKD Australia, Westmead Medical Research Foundation) and Chair, Scientific Advisory Board, PKD Australia. RP declares he is site investigator of clinical trials sponsored by Sanofi, Kadmon, Reata, Otsuka and the US Department of Defense (TAME PKD), and section editor for Cystic Kidney Disease, UpToDate.
Funding Information:
Funding The study was financially supported by a grant from Polycystic Kidney Disease Foundation of Australia and the National Health and Medical Research Council (NHMRC) Better Evidence and Translation in Chronic Kidney Disease (BEAT-CKD) Program (1092957), UMR INSERM 1246-SPHERE Methods in Patient-centered Outcomes and Health Research, and Research of Korea Center for Disease Control and Prevention (2016E3300201). AT is supported by an NHMRC Fellowship (1106716). DJ is supported by an NHMRC Practitioner Fellowship (1117534). TG is supported by an NHMRC Postgraduate Scholarship (1169149). MH is funded as a Post-Doctoral Fellow through the NHMRC BEAT-CKD Program Grant (APP1092957). KEM is supported by an NHMRC Postgraduate Scholarship (1151343). YC is supported by an NHMRC Early Career Fellowship (1126256). AV receives grant support from the NHMRC Medical Postgraduate Scholarship (1114539) and the Royal Australasian College of Physicians (Jacquot NHMRC Award for Excellence).
Publisher Copyright:
©
PY - 2020/10/10
Y1 - 2020/10/10
N2 - Background and objectives Presymptomatic testing is available for early diagnosis of hereditary autosomal dominant polycystic kidney disease (ADPKD). However, the complex ethical and psychosocial implications can make decision-making challenging and require an understanding of patients' values, goals and priorities. This study aims to describe patient and caregiver beliefs and expectations regarding presymptomatic testing for ADPKD. Design, setting and participants 154 participants (120 patients and 34 caregivers) aged 18 years and over from eight centres in Australia, France and Korea participated in 17 focus groups. Transcripts were analysed thematically. Results We identified five themes: Avoiding financial disadvantage (insecurity in the inability to obtain life insurance, limited work opportunities, financial burden); futility in uncertainty (erratic and diverse manifestations of disease limiting utility, taking preventive actions in vain, daunted by perplexity of results, unaware of risk of inheriting ADPKD); lacking autonomy and support in decisions (overwhelmed by ambiguous information, medicalising family planning, family pressures); seizing control of well-being (gaining confidence in early detection, allowing preparation for the future, reassurance in family resilience); and anticipating impact on quality of life (reassured by lack of symptoms, judging value of life with ADPKD). Conclusions For patients with ADPKD, presymptomatic testing provides an opportunity to take ownership of their health through family planning and preventive measures. However, these decisions can be wrought with tensions and uncertainty about prognostic implications, and the psychosocial and financial burden of testing. Healthcare professionals should focus on genetic counselling, mental health and providing education to patients' families to support informed decision-making. Policymakers should consider the cost burden and risk of discrimination when informing government policies. Finally, patients are recommended to focus on self-care from an early age.
AB - Background and objectives Presymptomatic testing is available for early diagnosis of hereditary autosomal dominant polycystic kidney disease (ADPKD). However, the complex ethical and psychosocial implications can make decision-making challenging and require an understanding of patients' values, goals and priorities. This study aims to describe patient and caregiver beliefs and expectations regarding presymptomatic testing for ADPKD. Design, setting and participants 154 participants (120 patients and 34 caregivers) aged 18 years and over from eight centres in Australia, France and Korea participated in 17 focus groups. Transcripts were analysed thematically. Results We identified five themes: Avoiding financial disadvantage (insecurity in the inability to obtain life insurance, limited work opportunities, financial burden); futility in uncertainty (erratic and diverse manifestations of disease limiting utility, taking preventive actions in vain, daunted by perplexity of results, unaware of risk of inheriting ADPKD); lacking autonomy and support in decisions (overwhelmed by ambiguous information, medicalising family planning, family pressures); seizing control of well-being (gaining confidence in early detection, allowing preparation for the future, reassurance in family resilience); and anticipating impact on quality of life (reassured by lack of symptoms, judging value of life with ADPKD). Conclusions For patients with ADPKD, presymptomatic testing provides an opportunity to take ownership of their health through family planning and preventive measures. However, these decisions can be wrought with tensions and uncertainty about prognostic implications, and the psychosocial and financial burden of testing. Healthcare professionals should focus on genetic counselling, mental health and providing education to patients' families to support informed decision-making. Policymakers should consider the cost burden and risk of discrimination when informing government policies. Finally, patients are recommended to focus on self-care from an early age.
KW - genetics
KW - medical education & training
KW - mental health
KW - nephrology
KW - paediatric nephrology
UR - http://www.scopus.com/inward/record.url?scp=85092752657&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092752657&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2020-038005
DO - 10.1136/bmjopen-2020-038005
M3 - Article
C2 - 33040007
AN - SCOPUS:85092752657
SN - 2044-6055
VL - 10
JO - BMJ Open
JF - BMJ Open
IS - 10
M1 - e038005
ER -